Call our 24 hours, seven days a week helpline at 800.272.3900
Let us connect you to professionals and support options near you. Please select an option below:
Use Current LocationUse Map Selector
In the News | HealthDay
Production aims to reduce Alzheimer’s disease stigma, educate and entertain underserved communities
Public health veteran and Association president signals continued focus on scientific progress and access for treatments for all who will benefit
Association Renews Urgent Call for CMS to Cover FDA-Approved Alzheimer’s Treatments
The FDA determined that additional data is required to reach a decision on accelerated approval of donanemab.
Leading researchers and community leaders convene in Tempe, Ariz. on February 8-9
As a patient advocacy group and evidence-based organization, the Alzheimer’s Association stands behind people living with Alzheimer’s.
Lisa Barnes, Ph.D. is the new deputy editor of Alzheimer's & Dementia, the Alzheimer's Association's journal.
The Alzheimer’s Association and AIM are proud to support the reintroduction of the NAPA Reauthorization Act and the Alzheimer’s Accountability & Investment Act.
An expert work group has developed an improved definition of clinical meaningfulness in Alzheimer's.
The Alzheimer’s Association and MATTER selected the winner and runners up in the competition to develop new tools for early assessment of Alzheimer's.
Part the Cloud, in partnership with the Alzheimer’s Association, was announced today as Best Health Fundraising Event in the 2nd Annual Anthem Awards.
The Alzheimer’s Association appreciates the generosity of the Erb Family Foundation and its ongoing commitment to advance Alzheimer’s and dementia research
The Centers for Medicare & Medicaid Services has refused to change its coverage of FDA-approved Alzheimer's treatments, despite significant new evidence.
Comprehensive Care for Alzheimer’s Act
Leaders of the U.S. POINTER Study announced a historic milestone: recruiting for the clinical trial has been successfully completed.
The Alzheimer’s Association is disappointed by the topline results from the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s (A4) Study of solanezumab.
We appreciate the agency’s thoughtful approach to making this decision.
The 2023 Facts and Figures report examines patients' and doctors' reluctance to address memory concerns, which hinders diagnosis and access to new treatments.
Comprehensive Care for Alzheimer’s Act introduced in U.S. House
The senators were each named the 2023 AIM Humanitarian of the Year at the National Alzheimer’s Dinner, during the AIM Advocacy Forum.
Comedian Discusses the Power of Laughter as a Caregiver
Ultraprocessed Foods May Speed Cognitive Decline
Animal Therapy Helps People Navigate Dementia
Museum Programs Inspire Those Facing Alzheimer’s
Actress' Struggle with Alzheimer’s Put the Disease in the Spotlight
Studies Show Discrimination May Cause Cognitive Decline
Alzheimer’s Association advocates flood Senate budget hearings to push HHS secretary to cover Alzheimer’s treatments.
New PSAs from the Ad Council, Alzheimer’s Association and NASCAR encourage families to talk about seeing a doctor together at the first signs of dementia.
The Alzheimer’s Association and bipartisan advocates urged the HHS secretary to cover FDA-approved Alzheimer’s treatments in this week's House budget hearings.
Take the Brain Tour